Search Result

Results for "

MET kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Met/HGFR (50) Akt (3) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (18) Autophagy (4) c-Kit (5) Caspase (1) EGFR (1) FLT3 (6) MEK (1) PDGFR (2) PI3K (1) Polo-like Kinase (PLK) (1) RAD51 (2) RET (2) RIP kinase (1) TAM Receptor (11) Trk Receptor (2) VEGFR (14)
By Research Areas:	Cancer (59) Inflammation/Immunology (1) Metabolic Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: c-Met/HGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18309

MET kinase-IN-4	c-Met/HGFR VEGFR	Cancer
MET kinase-IN-4 is an orally active **Met kinase** inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC₅₀ value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer .

HY-131065

MET kinase-IN-2

c-Met/HGFR Cancer

MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC₅₀ of 7.4 nM. MET kinase-IN-2 has antitumor activity .

MET kinase-IN-2	c-Met/HGFR	Cancer
MET kinase-IN-2 is a potent, selective, orally bioavailable **MET kinase** inhibitor with an IC₅₀ of 7.4 nM. MET kinase-IN-2 has antitumor activity .

HY-146884

MET kinase-IN-3	c-Met/HGFR VEGFR	Cancer
MET kinase-IN-3 (compound 8) is an orally active and potent *MET* inhibitor, with an IC₅₀ of 9.8 nM. MET kinase-IN-3 shows good and broad-spectrum antiproliferative activity against cancer cell lines .

HY-148279

c-Met-IN-15

c-Met/HGFR Cancer

c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

c-Met-IN-15	c-Met/HGFR	Cancer
c-Met-IN-15 (compound S3) is a c-Met kinase inhibitor. c-Met-IN-15 inhibits c-Met kinase activity of 21.1% at the concentration of 10 μM .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II *c-Met* kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-124267

Zgwatinib SOMG-833	c-Met/HGFR	Cancer
Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive *c-MET* inhibitor, with an IC₅₀ of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research .

HY-50686

Tivantinib

5+ Cited Publications

ARQ 197; (3R,4R)-ARQ 198
c-Met/HGFR Apoptosis Cancer

Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a K_i of 355 nM.

Tivantinib 5+ Cited Publications ARQ 197; (3R,4R)-ARQ 198	c-Met/HGFR Apoptosis	Cancer
Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-111050

JNJ-38877618	c-Met/HGFR	Cancer
JNJ-38877618 is a potent, highly selective, orally bioavailable *Met* kinase inhibitor with IC₅₀s of 2 and 3 nM for wild type and mutant Met, respectively.

HY-18696

AMG-337	c-Met/HGFR Caspase Apoptosis	Cancer
AMG-337 is a potent, orally active, selective **MET kinase** inhibitor with IC₅₀ values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .

HY-12017

PF-04217903 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-12017A

PF-04217903 mesylate 2 Publications Verification	c-Met/HGFR	Cancer
PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-147218

TAM&Met-IN-1	c-Met/HGFR TAM Receptor	Cancer
TAM&Met-IN-1 is a potent TAM and *c-Met* kinase inhibitor with IC₅₀ values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. TAM&Met-IN-1 can be used for researching anticancer .

HY-116000

Glumetinib 1 Publications Verification Gumarontinib; SCC244	c-Met/HGFR	Cancer
Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive *c-Met* inhibitor with an IC₅₀ of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .

HY-12019

SGX-523 5+ Cited Publications	c-Met/HGFR	Cancer
SGX523 is a exquisitely selective and ATP-competitive *MET* inhibitor. SGX523 potently inhibits MET with an IC₅₀ of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity .

HY-12017B

PF-04217903 phenolsulfonate	c-Met/HGFR	Cancer
PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties .

HY-147259

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective *c-Met* kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent *c-Met* kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10338

Foretinib 10+ Cited Publications XL880; GSK1363089; GSK089; EXEL-2880	VEGFR c-Met/HGFR	Cancer
Foretinib is a multi-target tyrosine kinase inhibitor with IC₅₀s of 0.4 nM and 0.9 nM for *Met* and KDR.

HY-150582

c-Met-IN-14	c-Met/HGFR c-Kit FLT3 Apoptosis	Cancer
c-Met-IN-14 (compound 26af) is a selective inhibitor of *c-Met* kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner .

HY-133083

BAY-474

c-Met/HGFR Cancer

BAY-474 is a tyrosine-protein kinase c-Met inhibitor. BAY-474 acts as an epigenetics probe .

BAY-474	c-Met/HGFR	Cancer
BAY-474 is a tyrosine-protein kinase *c-Met* inhibitor. BAY-474 acts as an epigenetics probe .

HY-50683

JNJ-38877605 3 Publications Verification	c-Met/HGFR	Metabolic Disease Cancer
JNJ-38877605 is an orally active ATP-competitive inhibitor of *c-Met* with an IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .

HY-13068

Golvatinib 4 Publications Verification E-7050	c-Met/HGFR VEGFR	Cancer
Golvatinib (E-7050) is a potent dual inhibitor of both *c-Met* and VEGFR2 kinases with IC₅₀s of 14 and 16 nM, respectively.

HY-76688

(Rac)-Tivantinib (Rac)-ARQ 197; (Rac)-ARQ 198	Others	Cancer
(Rac)-Tivantinib is the isomer of Tivantinib (HY-50686), and can be used as an experimental control. Tivantinib is a highly selective *c-Met* tyrosine kinase inhibitor with a K_i of 355 nM.

HY-125017

Bozitinib 1 Publications Verification PLB-1001; CBT-101; Vebreltinib	c-Met/HGFR	Cancer
Bozitinib (PLB-1001) is a highly selective *c-MET* kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .

HY-13404

Capmatinib 5+ Cited Publications INC280; INCB28060	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404B

Capmatinib hydrochloride INC280 hydrochloride; INCB-28060 hydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404C

Capmatinib dihydrochloride hydrate 5+ Cited Publications INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-13404A

Capmatinib dihydrochloride INC280 dihydrochloride; INCB28060 dihydrochloride	c-Met/HGFR Apoptosis	Cancer
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive *c-Met* kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase .

HY-146274

c-Met-IN-10	c-Met/HGFR Apoptosis	Cancer
c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC₅₀ value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC₅₀s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .

HY-11107

PHA-665752 10+ Cited Publications	c-Met/HGFR Autophagy Apoptosis	Cancer
PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of *c-Met* kinase (K_i=4 nM; IC₅₀=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis and cell cycle arrest, and exhibits cytoreductive antitumor activity .

HY-12076

BMS 777607 5+ Cited Publications BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a *Met-related* inhibitor for *c-Met, Axl, Ron* and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .

HY-12423

Pamufetinib TAS-115	VEGFR c-Met/HGFR	Cancer
Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC₅₀s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

HY-107145

Ningetinib Tosylate	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-107145A

Ningetinib	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for *c-Met, VEGFR2* and Axl, respectively.

HY-12423A

Pamufetinib mesylate TAS-115 mesylate	VEGFR c-Met/HGFR	Cancer
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC₅₀s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

HY-13299

MK-8033 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 is an orally active ATP competitive *c-Met/Ron* dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-13299A

MK-8033 hydrochloride 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 hydrochloride is an orally active ATP competitive *c-Met/Ron* dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-16446

SAR125844	c-Met/HGFR PI3K Akt MEK Apoptosis	Cancer
SAR125844 is a potent, selective, and ATP-competitive *MET* kinase inhibitor with the value of IC₅₀ is 4.2 nM and K_i is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent *MET/SMO* dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-19642

Glesatinib MGCD265	TAM Receptor c-Met/HGFR	Cancer
Glesatinib (MGCD265) is an orally active, potent *MET/SMO* dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-10991

MGCD-265 analog 1 Publications Verification	c-Met/HGFR VEGFR Apoptosis	Cancer
MGCD-265 analog is a potent and oral active inhibitor of *c-Met* and VEGFR2 tyrosine kinases, with IC₅₀s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity .

HY-12044

Cabozantinib S-malate Maximum Cited Publications 38 Publications Verification XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, *c-Met, Kit, Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual *c-Met* and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-147413

Unecritinib TQ-B3101	EGFR	Cancer
Unecritinib (TQ-B3101) is a potent EGFR tyrosine kinase inhibitor. Unecritinib shows anticancer activity. Unecritinib inhibits ALK, ROS1, and MET. Unecritinib has the potential for the research of solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma .

HY-16590

X-376 1 Publications Verification	Anaplastic lymphoma kinase (ALK) c-Met/HGFR	Cancer
X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC₅₀=0.61 nM). X-376 is a less potent inhibitor of *MET* (IC₅₀=0.69 nM). X-376 displays potent anti-tumor activity .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-13260

CCT128930 3 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-155544

Antitumor agent-111	c-Met/HGFR	Cancer
Antitumor agent-111 (compound 46) is an *c-Met* kinase inhibitor (IC₅₀=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis .

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including *MET, VEGFR2, AXL* and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-77493

(rel)-Tivantinib (rel)-ARQ 197; (rel)-(3R,4R)-ARQ 198	Others	Cancer
(rel)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (rel)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: